Evolution Biotechnologies announces publication of open-access paper on the selection of disease targets for phage therapy

Evolution Biotechnologies (www.evolutionbiotech.com), the UK and US-based company extending the use of biological control into medically important areas, today announced the publication of an invited paper written by Dr. David Harper, its Chief Executive Officer, as part of a special edition of the journal “Viruses”. The special edition is edited by Dr. Harald Brüssow and is focussed on “Hurdles for Phage Therapy (PT) to Become a Reality”. The paper, entitled “Criteria for Selecting Suitable Infectious Diseases for Phage Therapy” (Viruses 2018, 10(4), 177; https://doi.org/10.3390/v10040177) can be viewed at http://www.mdpi.com/1999-4915/10/4/177.

About Evolution Biotechnologies

Evolution Biotechnologies (UK company 09473027) has been established to extend the application of biological control from its agricultural roots into areas of biomedical importance. The company’s initial targets have both significant unmet need and high market potential. The first stage of Evolution’s work is based on the outcomes of a successful feasibility study on biological control of the house dust mite. The company is also workong to develop further biological controls, including phage therapy for the antibiotic resistant superbug Pseudomonas aeruginosa. This will initially target disease in companion animals as a basis for the later development of human therapeutics.

About biological control

Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”. Biological control methodologies have been extensively used in the agricultural and food safety sectors and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date.

Forward-looking statements

This document contains certain forward-looking statements – i.e., statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts;

Email:      enquiries@evolutionbiotech.com

Website:   www.evolutionbiotech.com

Evolution Biotechnologies announces positive outcome of international patent search and examination on key patent filing

Bedford, UK, November 14th 2017

­Evolution Biotechnologies (www.evolutionbiotech.com), the UK and US-based company extending the use of biological control into medically important areas, today announced the highly positive outcome of the international (PCT) stage search and examination of its key patent filing PCT/GB2016/052455, “Acaricides”. The examination, conducted by the European Patent Office (EPO), confirmed the broad claim to a method of treating or preventing a house dust mite infestation using an acaricidal infectious agent as both novel and inventive. This is a key step towards obtaining broad protection for the work of the company in controlling house dust mites, a major cause of asthma and other allergic conditions in both humans and companion animals.

Dr. David Harper, Chief Executive Officer of Evolution, said “This is an important step for the company, validating our work to date and taking us a lot closer to developing products to benefit millions of asthmatics worldwide. I look forward to progressing this application through the national stages and on to award, based on this very promising result.”

About Evolution Biotechnologies

Evolution Biotechnologies (UK company 09473027) has been established to extend the application of biological control from its agricultural roots into areas of biomedical importance. The company’s initial targets have both significant unmet need and high market potential. The first stage of Evolution’s work is based on the outcomes of a successful feasibility study on biological control of the house dust mite. The company is also workong to develop further biological controls, including phage therapy for the antibiotic resistant superbug Pseudomonas aeruginosa. This will initially target disease in companion animals as a basis for the later development of human therapeutics.

About biological control

Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”. Biological control methodologies have been extensively used in the agricultural and food safety sectors and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date.

Forward-looking statements

This document contains certain forward-looking statements – i.e., statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts;

Email:      enquiries@evolutionbiotech.com

Website:   www.evolutionbiotech.com

Interview with Dr. David Harper and Dr. Robert Atterbury of Nottingham University.

Bedford, UK, and Austin, Texas; November 14th 2016

Evolution Biotechnologies (www.evolutionbiotech.com), the company working to expand the use of biological control into medically important areas, today announces the release of a video interview with its Chief Officer, Dr. David Harper, conducted by Dr. Robert Atterbury of Nottingham University.
The interview forms part of the University’s online course on Antimicrobial Resistance in the Food Chain, which will launch on Monday 14th November: www.futurelearn.com/courses/antimicrobial-resistance-food-chain/. The interview can also be viewed by clicking on the following link  https://www.youtube.com/watch?v=DxKhlc4adKk.

About Evolution Biotechnologies
Evolution Biotechnologies (UK company 09473027 / US company 6050853) has been established to extend the application of biological control from its agricultural roots into areas of biomedical importance. The company’s initial targets have both significant unmet need and high market potential. The first stage of Evolution’s work is based on developing biological controls for of the house dust mite, with the company now expanding into phage therapy, a highly promising approach to controlling antimicrobial resistance. The development of additional technologies is planned for the future.

About biological control
Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”. Biological control methodologies have been extensively used in the agricultural sector and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date.

Forward-looking statements
This document contains certain forward-looking statements – i.e., statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts;
Email: enquiries@evolutionbiotech.com
Website: www.evolutionbiotech.com

Dr David Harper presents “Bacteriophage therapy – Still promising but not (yet) delivering” at Euroscicon

Bedford, UK, and Austin, Texas; November 10th 2016
Evolution Biotechnologies (www.evolutionbiotech.com), the company working to expand the use of biological control into medically important areas, today announces a presentation by its Chief Officer, Dr. David Harper.
The presentation, entitled “Bacteriophage therapy – Still promising but not (yet) delivering” is to be given on Thursday 10th November via webex at the virtual conference held by Euroscicon on Developing antibiotic alternatives: A discussion of new approaches to overcoming antimicrobial resistance.

About Evolution Biotechnologies
Evolution Biotechnologies (UK company 09473027 / US company 6050853) has been established to extend the application of biological control from its agricultural roots into areas of biomedical importance. The company’s initial targets have both significant unmet need and high market potential. The first stage of Evolution’s work is based on developing biological controls for of the house dust mite, with the company now expanding into phage therapy, a highly promising approach to controlling antimicrobial resistance. The development of additional technologies is planned for the future.

About biological control
Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”. Biological control methodologies have been extensively used in the agricultural sector and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date.

Forward-looking statements
This document contains certain forward-looking statements – i.e., statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts;
Email: enquiries@evolutionbiotech.com
Website: www.evolutionbiotech.com

Evolution Biotechnologies announces presentation by Chief Officer Dr. David Harper

Bedford, UK, and Austin, Texas; September 14th 2016

­Evolution Biotechnologies (www.evolutionbiotech.com), the company working to expand the use of biological control into medically important areas, today announces a presentation by its Chief Officer, Dr. David Harper.

The presentation, entitled “Bacteriophages as Biological Control Agents” is to be given on Friday 16th September at the conference on “Phage-based Technologies Against Antimicrobial Resistance” organised under the EU FP7 EVOPROG programme, in Stratford-upon-Avon, UK.

About Evolution Biotechnologies

Evolution Biotechnologies (UK company 09473027 / US company 6050853) has been established to extend the application of biological control from its agricultural roots into areas of biomedical importance. The company’s initial targets have both significant unmet need and high market potential. The first stage of Evolution’s work is based on developing biological controls for of the house dust mite, with the company now expanding into phage therapy, a highly promising approach to controlling antimicrobial resistance. The development of additional technologies is planned for the future.

About biological control

Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”. Biological control methodologies have been extensively used in the agricultural sector and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date.

Forward-looking statements

This document contains certain forward-looking statements – i.e., statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts;

Email:      enquiries@evolutionbiotech.com

Website:   www.evolutionbiotech.com

 

Evolution Biotechnologies announces that its UK patent application for house dust mites has progressed to the international stage

Evolution Biotechnologies (www.evolutionbiotech.com), the company working to expand the use of biological control into medically important areas, today announced that its UK patent application, “Acaricides” (GB1513981.9), relating to biological controls for house dust mites has progressed to the international stage as PCT application PCT/GB2016/052455. The PCT filing incorporates both data from the previous successful feasibility study and also recent findings identifying a biological agent capable of targeting multiple mite species.

Dr. David Harper, Chief Officer of Evolution, said “we are delighted to be able to incorporate the recent and exciting findings from our HDM research group, headed by Senior Scientist Dr. Victor Brugman, into this PCT filing. This illustrates the real progress that Evolution is making in developing its novel approach to control house dust mites, with the potential to bring real benefit to the hundreds of millions of asthma sufferers around the world.”

About Evolution Biotechnologies

Evolution Biotechnologies (UK company 09473027 / US company 6050853) has been established to extend the application of biological control from its agricultural roots into areas of biomedical importance. The company’s initial targets have both significant unmet need and high market potential. The first stage of Evolution’s work will be based on the outcomes of a successful feasibility study on biological control of the house dust mite. The potential for developing a biological control for the bed bug will also be evaluated, along with the potential for additional targets.

About biological control

Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”. Biological control methodologies have been extensively used in the agricultural sector and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date.

Forward-looking statements

This document contains certain forward-looking statements – i.e., statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

mail:       enquiries@evolutionbiotech.com

Website: www.evolutionbiotech.com

Evolution Biotechnologies announces sponsorship of EMBO Viruses of Microbes meeting, Liverpool, UK, 18-22 July 2016

Bedford, UK, and Austin, Texas; July 8th 2016

Evolution Biotechnologies (www.evolutionbiotech.com), the company working to expand the use of biological control into medically important areas, today announced its sponsorship of the forthcoming EMBO Vpromoiruses of Microbes (#EMBOVoM2016) meeting in Liverpool (http://events.embo.org/16-virus-microbe/ ).

The company will attend the meeting both to promote its new activities in the area and to recruit staff for its expanded operations.

Dr. David Harper, Chief Officer of Evolution, said “I am delighted that the company is supporting this important meeting, and look forward to attending along with other company staff.”

About Evolution Biotechnologies

Evolution Biotechnologies (UK company 09473027 / US company 6050853) has been established to extend the application of biological control from its agricultural roots into areas of biomedical importance. The company’s initial targets have both significant unmet need and high market potential. The first stage of Evolution’s work is based on developing biological controls for of the house dust mite, with the company now expanding into phage therapy, a highly promising approach to controlling antimicrobial resistance. The development of additional technologies is planned for the future.

About biological control

Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”. Biological control methodologies have been extensively used in the agricultural sector and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date.

Forward-looking statements

This document contains certain forward-looking statements – i.e., statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts;

Email:      enquiries@evolutionbiotech.com

Website:   www.evolutionbiotech.com

Evolution Biotechnologies announces expansion into phage therapy

­Evolution Biotechnologies (www.evolutionbiotech.com), the company working to expand the use of biological control into medically important areas, today announced an important development in its operations, with the establishment of its therapeutic division. This will work to develop the therapeutic use of bacteria-killing viruses, or bacteriophages, an approach known as phage therapy. This is recognised as a highly promising approach to the control of antibiotic-resistant bacterial infections.

Dr. David Harper, the founder and Chief Officer of Evolution has unique experience in this area, having previously run the only modern clinical trial to demonstrate the efficacy of the approach, and demonstrated the effectiveness of phage therapy in controlling damaging infections in both companion dogs and humans.  The initial target will be the development of a treatment for ear infections in companion dogs, with additional markets following on. Work will be based at the planned company facility in Austin, Texas with a trials support unit based at the company’s existing Colworth site in the UK.

Dr. David Harper, Chief Officer of Evolution, said “I am delighted to be returning to the critically important area of fighting antimicrobial resistance. Phage therapy has been identified as one of the most promising approaches to addressing this crisis. By leveraging prior experience Evolution Biotechnologies is in a unique position to develop new medicines in this vital area.”

About Evolution Biotechnologies

Evolution Biotechnologies (UK company 09473027 / US company 6050853) has been established to extend the application of biological control from its agricultural roots into areas of biomedical importance. The company’s initial targets have both significant unmet need and high market potential. The first stage of Evolution’s work is based on developing biological controls for of the house dust mite, with the company now expanding into phage therapy, a highly promising approach to controlling antimicrobial resistance. The development of additional technologies is planned for the future.

About biological control

Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”. Biological control methodologies have been extensively used in the agricultural sector and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date.

Forward-looking statements

This document contains certain forward-looking statements – i.e., statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts;

Email:      enquiries@evolutionbiotech.com

Website:   www.evolutionbiotech.com

Evolution Biotechnologies announces formation of U.S. subsidiary

Bedford, UK, and Austin, Texas; June 10,  2016

Evolution Biotechnologies (www.evolutionbiotech.com), the company working to expand the use of biological control into medically important areas, today announced the formation of its US-based subsidiary, Evolution Biotechnologies Inc. of Delaware. The company has been established to support operations at the planned company facility in Austin, Texas.

Aaron Gunn, Chief Operating Officer of Evolution, said “This is an important step for the company, and will help facilitate our expansion into the United States.”

 

About Evolution Biotechnologies

Evolution Biotechnologies (UK company 09473027 / US company 6050853) has been established to extend the application of biological control from its agricultural roots into areas of biomedical importance. The company’s initial targets have both significant unmet need and high market potential. The first stage of Evolution’s work will be based on the outcomes of a successful feasibility study on biological control of the house dust mite. The potential for developing a biological control for the bed bug will also be evaluated, along with the potential for additional targets.

 

About biological control

Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”. Biological control methodologies have been extensively used in the agricultural sector and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date.

 

Forward-looking statements

This document contains certain forward-looking statements – i.e., statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

mail:       enquiries@evolutionbiotech.com

Website: www.evolutionbiotech.com

Evolution Biotechnologies announces appointment of Dr. Victor Brugman as senior scientist on its house dust mite control project

Evolution Biotechnologies (www.evolutionbiotech.com), the UK-based company established to expand the use of biological control into medically important areas, today announced the appointment of Dr. Victor Brugman as senior scientist on its dust mite control project. Dr. Brugman will be working with the ARCTEC unit at the London School of Hygiene and Tropical Medicine in London in the early stages of the work, and will be moving to the company’s central facility at Colworth Science Park later in the year.
Dr. David Harper, Chief Officer of Evolution, said “This is an important step for the company, I would like to welcome Dr. Brugman to the company at this exciting stage of its development. He brings a wealth of experience to the company which will be directly applicable to this project and to our long term aims.”

About Evolution Biotechnologies
Evolution Biotechnologies (UK company 09473027) has been established to extend the application of biological control from its agricultural roots into areas of biomedical importance. The company’s initial targets have both significant unmet need and high market potential. The first stage of Evolution’s work will be based on the outcomes of a successful feasibility study on biological control of the house dust mite. The potential for developing a biological control for the bed bug will also be evaluated, along with the potential for additional targets.

About biological control
Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”. Biological control methodologies have been extensively used in the agricultural sector and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date.

Forward-looking statements
This document contains certain forward-looking statements – i.e., statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts;
Email: enquiries@evolutionbiotech.com
Website: www.evolutionbiotech.com